Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-Authorisation Safety Study of Voncento/Biostate/Aleviate in Male Patients with Haemophilia A
2016-002510-50Phase 4Terminated
- Sponsor
- CSL Limited
- Start
- Sep 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of factor viii + von Willebrand factor in hemophilia A, sponsored by CSL Limited. Primary endpoint: Incidence of FVIII inhibitor development. Started Sep 2017; status: terminated.
02
Drugs
factor viii + von Willebrand factor
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2016-002510-50.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002510-50.